## Randi J Hagerman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/14325/publications.pdf

Version: 2024-02-01

304 papers 22,875 citations

82 h-index 136 g-index

320 all docs

320 docs citations

times ranked

320

10318 citing authors

#	Article	IF	CITATIONS
1	Hypermobile Ehlers-Danlos syndrome (hEDS) phenotype in fragile X premutation carriers: case series. Journal of Medical Genetics, 2022, 59, 687-690.	1.5	5
2	Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon. Annual Review of Pharmacology and Toxicology, 2022, 62, 365-381.	4.2	6
3	Hispanoâ€American Brain Bank on Neurodevelopmental Disorders: An initiative to promote brain banking, research, education, and outreach in the field of neurodevelopmental disorders. Brain Pathology, 2022, 32, e13019.	2.1	3
4	Recent research in fragile X-associated tremor/ataxia syndrome. Current Opinion in Neurobiology, 2022, 72, 155-159.	2.0	1
5	An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics, 2022, 19, 248-262.	2.1	47
6	Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation. Frontiers in Neurology, 2022, 13, 797649.	1.1	7
7	Fragile X Syndrome: From Molecular Aspect to Clinical Treatment. International Journal of Molecular Sciences, 2022, 23, 1935.	1.8	27
8	Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome. Journal of Neurodevelopmental Disorders, 2022, 14, 23.	1.5	8
9	Prosaccade and Antisaccade Behavior in Fragile Xâ€associated Tremor/Ataxia Syndrome Progression. Movement Disorders Clinical Practice, 2022, 9, 473-478.	0.8	1
10	Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments. Neurotherapeutics, 2021, 18, 265-283.	2.1	15
11	Surveillance and prevalence of fragile X syndrome in Indonesia. Intractable and Rare Diseases Research, 2021, 10, 11-16.	0.3	4
12	Inequities in diagnosis of Fragile X syndrome in Colombia. Journal of Applied Research in Intellectual Disabilities, 2021, 34, 830-839.	1.3	3
13	Cerebral Microbleeds in Fragile X–Associated Tremor/Ataxia Syndrome. Movement Disorders, 2021, 36, 1935-1943.	2.2	17
14	Fragile X syndrome. Current Biology, 2021, 31, R273-R275.	1.8	13
15	Fragile X-associated tremor/ataxia syndrome: pathophysiology and management. Current Opinion in Neurology, 2021, 34, 541-546.	1.8	22
16	Deficits in Prenatal Serine Biosynthesis Underlie the Mitochondrial Dysfunction Associated with the Autism-Linked FMR1 Gene. International Journal of Molecular Sciences, 2021, 22, 5886.	1.8	10
17	Brain Atrophy and White Matter Damage Linked to Peripheral Bioenergetic Deficits in the Neurodegenerative Disease FXTAS. International Journal of Molecular Sciences, 2021, 22, 9171.	1.8	8
18	Case Report: Coexistence of Alzheimer-Type Neuropathology in Fragile X-Associated Tremor Ataxia Syndrome. Frontiers in Neuroscience, 2021, 15, 720253.	1.4	8

#	Article	IF	CITATIONS
19	Sulforaphane improves mitochondrial metabolism in fibroblasts from patients with fragile X-associated tremor and ataxia syndrome. Neurobiology of Disease, 2021, 157, 105427.	2.1	9
20	FMRP Levels in Human Peripheral Blood Leukocytes Correlates with Intellectual Disability. Diagnostics, 2021, 11, 1780.	1.3	6
21	Increased Pain Symptomatology Among Females vs. Males With Fragile X-Associated Tremor/Ataxia Syndrome. Frontiers in Psychiatry, 2021, 12, 762915.	1.3	6
22	Fragile X Premutation: Medications, Therapy and Lifestyle Advice. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1689-1699.	0.4	5
23	Raising Knowledge and Awareness of Fragile X Syndrome in Serbia, Georgia, and Colombia: A Model for Other Developing Countries?. Yale Journal of Biology and Medicine, 2021, 94, 559-571.	0.2	1
24	Interaction between ventricular expansion and structural changes in the corpus callosum and putamen in males with FMR1 normal and premutation alleles. Neurobiology of Aging, 2020, 86, 27-38.	1.5	10
25	Fragile X syndrome and associated disorders: Clinical aspects and pathology. Neurobiology of Disease, 2020, 136, 104740.	2.1	80
26	Cerebellar-cortical function and connectivity during sensorimotor behavior in aging FMR1 gene premutation carriers. Neurolmage: Clinical, 2020, 27, 102332.	1.4	10
27	Cardiovascular Problems in the Fragile X Premutation. Frontiers in Genetics, 2020, 11, 586910.	1.1	11
28	Characterization of the Metabolic, Clinical and Neuropsychological Phenotype of Female Carriers of the Premutation in the X-Linked FMR1 Gene. Frontiers in Molecular Biosciences, 2020, 7, 578640.	1.6	12
29	Cortical gyrification and its relationships with molecular measures and cognition in children with the FMR1 premutation. Scientific Reports, 2020, 10, 16059.	1.6	3
30	Women with Fragile X–associated Tremor/Ataxia Syndrome. Movement Disorders Clinical Practice, 2020, 7, 910-919.	0.8	13
31	Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis. Brain Sciences, 2020, 10, 629.	1.1	21
32	Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome. Brain Sciences, 2020, 10, 361.	1.1	3
33	Fragile X associated neuropsychiatric disorders in a male without FXTAS. Intractable and Rare Diseases Research, 2020, 9, 113-118.	0.3	5
34	Parkinsonism Versus Concomitant Parkinson's Disease in Fragile X–Associated Tremor/Ataxia Syndrome. Movement Disorders Clinical Practice, 2020, 7, 413-418.	0.8	13
35	<p>Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer's Disease</p> . Clinical Interventions in Aging, 2020, Volume 15, 285-292.	1.3	7
36	Ataxia as the Major Manifestation of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Case Series. Biomedicines, 2020, 8, 136.	1.4	7

#	Article	IF	CITATIONS
37	Elevated FMR1-mRNA and lowered FMRP – A double-hit mechanism for psychiatric features in men with FMR1 premutations. Translational Psychiatry, 2020, 10, 205.	2.4	20
38	Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications. International Journal of Molecular Sciences, 2020, 21, 4391.	1.8	52
39	Developmental aspects of FXAND in a man with the <i>FMR1</i> premutation. Molecular Genetics & Genomic Medicine, 2020, 8, e1050.	0.6	5
40	Spontaneous Coronary Artery DissectionÂin Females With the FragileÂXÂFMR1ÂPremutation. JACC: Case Reports, 2020, 2, 40-44.	0.3	8
41	Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder. Frontiers in Genetics, 2020, 11, 308.	1.1	3
42	Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. Journal of Neurodevelopmental Disorders, 2020, 12, 12.	1.5	44
43	Human Cerebral Cortex Proteome of Fragile X-Associated Tremor/Ataxia Syndrome. Frontiers in Molecular Biosciences, 2020, 7, 600840.	1.6	11
44	A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatric Neurology, 2020, 110, 30-41.	1.0	50
45	Double Genetic Hit: Fragile X Syndrome and Partial Deletion of Protein Patched Homolog 1 Antisense as Cause of Severe Autism Spectrum Disorder. Journal of Developmental and Behavioral Pediatrics, 2020, 41, 724-728.	0.6	7
46	General Anesthetic Use in Fragile X Spectrum Disorders. Journal of Neurosurgical Anesthesiology, 2019, 31, 285-290.	0.6	16
47	New Targeted Treatments for Fragile X Syndrome. Current Pediatric Reviews, 2019, 15, 251-258.	0.4	31
48	Fragile X-associated neuropsychiatric disorders: a case report. Future Neurology, 2019, 14, FNL14.	0.9	5
49	A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. Frontiers in Psychiatry, 2019, 10, 810.	1.3	22
50	Metformin treatment in young children with fragile X syndrome. Molecular Genetics & Denomic Medicine, 2019, 7, e956.	0.6	39
51	Composition of the Intranuclear Inclusions of Fragile X-associated Tremor/Ataxia Syndrome. Acta Neuropathologica Communications, 2019, 7, 143.	2.4	48
52	Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome. PLoS ONE, 2019, 14, e0209984.	1.1	22
53	Cognitive and behavioral improvement in adults with fragile X syndrome treated with metforminâ€ŧwo cases. Molecular Genetics & mp; Genomic Medicine, 2019, 7, e00745.	0.6	21
54	Turning the tide on targeted treatments for neurodevelopmental disorders. Neurology, 2019, 92, 741-742.	1.5	2

#	Article	IF	CITATIONS
55	De novo and biallelic DEAF1 variants cause a phenotypic spectrum. Genetics in Medicine, 2019, 21, 2059-2069.	1.1	20
56	Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature. Cannabis and Cannabinoid Research, 2019, 4, 3-9.	1.5	32
57	Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS ONE, 2019, 14, e0226811.	1.1	52
58	Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. Molecular Neurobiology, 2019, 56, 3702-3713.	1.9	28
59	Widespread RNA editing dysregulation in brains from autistic individuals. Nature Neuroscience, 2019, 22, 25-36.	7.1	161
60	Fragile X syndrome and connective tissue dysregulation. Clinical Genetics, 2019, 95, 262-267.	1.0	25
61	Increased severity of fragile X spectrum disorders in the agricultural community of Ricaurte, Colombia. International Journal of Developmental Neuroscience, 2019, 72, 1-5.	0.7	10
62	SÃndrome X frágil: presentación clÃnica, patologÃa y tratamiento. Gaceta Medica De Mexico, 2019, 156, 60-66.	0.5	16
63	Fragile X checklists: A metaâ€analysis and development of a simplified universal clinical checklist. Molecular Genetics & Genomic Medicine, 2018, 6, 526-532.	0.6	15
64	Genetic cluster of fragile X syndrome in a Colombian district. Journal of Human Genetics, 2018, 63, 509-516.	1.1	27
65	Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. Human Molecular Genetics, 2018, 27, 2039-2051.	1.4	51
66	Distance delivery of a spoken language intervention for school-aged and adolescent boys with fragile X syndrome. Developmental Neurorehabilitation, 2018, 21, 48-63.	0.5	31
67	Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. Neuropsychopharmacology, 2018, 43, 503-512.	2.8	102
68	Rare <i>FMR1</i> gene mutations causing fragile X syndrome: A review. American Journal of Medical Genetics, Part A, 2018, 176, 11-18.	0.7	65
69	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nature Reviews Drug Discovery, 2018, 17, 280-299.	21.5	247
70	Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Scientific Reports, 2018, 8, 16970.	1.6	33
71	Microglial cell activation and senescence are characteristic of the pathology FXTAS. Movement Disorders, 2018, 33, 1887-1894.	2.2	19
72	Best Practices in Fragile X Syndrome Treatment Development. Brain Sciences, 2018, 8, 224.	1.1	37

#	Article	IF	Citations
73	Fragile X-Associated Neuropsychiatric Disorders (FXAND). Frontiers in Psychiatry, 2018, 9, 564.	1.3	132
74	Cognitive Deficits and Associated ERP N400 Abnormalities in FXTAS With Parkinsonism. Frontiers in Genetics, 2018, 9, 327.	1.1	0
75	Impact of FMR1 Premutation on Neurobehavior and Bioenergetics in Young Monozygotic Twins. Frontiers in Genetics, $2018, 9, 338$ .	1.1	17
76	Presence of Middle Cerebellar Peduncle Sign in FMR1 Premutation Carriers Without Tremor and Ataxia. Frontiers in Neurology, 2018, 9, 695.	1.1	13
77	Middle Cerebellar Peduncle Width—A Novel MRI Biomarker for FXTAS?. Frontiers in Neuroscience, 2018, 12, 379.	1.4	16
78	Fentanyl overdose in a female with the premutation and FXTAS. , 2018, 1, .		3
79	Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome. Brain and Development, 2017, 39, 483-492.	0.6	29
80	Genetics, white matter, and cognition. Neurology, 2017, 88, 2070-2071.	1.5	8
81	Clinical and molecular correlates in fragile X premutation females. ENeurologicalSci, 2017, 7, 49-56.	0.5	13
82	<scp>T</scp> wo <scp>FMR</scp> 1 premutation cases without nuclear inclusions. Movement Disorders, 2017, 32, 1328-1329.	2.2	5
83	Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation. Neurobiology of Aging, 2017, 55, 11-19.	1.5	46
84	Fragile X syndrome. Nature Reviews Disease Primers, 2017, 3, 17065.	18.1	490
85	Implications of the <i>FMR1</i> Premutation for Children, Adolescents, Adults, and Their Families. Pediatrics, 2017, 139, S172-S182.	1.0	38
86	Size and methylation mosaicism in males with Fragile X syndrome. Expert Review of Molecular Diagnostics, 2017, 17, 1023-1032.	1.5	47
87	Arbaclofen in fragile X syndrome: results of phase 3 trials. Journal of Neurodevelopmental Disorders, 2017, 9, 3.	1.5	135
88	Fragile X targeted pharmacotherapy: lessons learned and future directions. Journal of Neurodevelopmental Disorders, 2017, 9, 7.	1.5	99
89	Children With Fragile X Syndrome Display Threat-Specific Biases Toward Emotion. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 487-492.	1.1	10
90	The Gut Microbiota and Autism Spectrum Disorders. Frontiers in Cellular Neuroscience, 2017, 11, 120.	1.8	311

#	Article	IF	CITATIONS
91	Prenatal Diagnosis of Fragile X: Can a Full Mutation Allele in the FMR1 Gene Contract to a Normal Size?. Frontiers in Genetics, 2017, 8, 158.	1.1	8
92	Fragile X Syndrome: Prevalence, Treatment, and Prevention in China. Frontiers in Neurology, 2017, 8, 254.	1.1	10
93	A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. Journal of Neurodevelopmental Disorders, 2017, 9, 26.	1.5	67
94	Fragile X syndrome and fragile X-associated disorders. F1000Research, 2017, 6, 2112.	0.8	38
95	Altered Redox Mitochondrial Biology in the Neurodegenerative Disorder Fragile X-Tremor/Ataxia Syndrome: Use of Antioxidants in Precision Medicine. Molecular Medicine, 2016, 22, 548-559.	1.9	56
96	The neurobiology of the Prader-Willi phenotype of fragile X syndrome. Intractable and Rare Diseases Research, 2016, 5, 255-261.	0.3	16
97	Premutation in the Fragile X Mental Retardation 1 (FMR1) Gene Affects Maternal Zn-milk and Perinatal Brain Bioenergetics and Scaffolding. Frontiers in Neuroscience, 2016, 10, 159.	1.4	24
98	Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers. Frontiers in Molecular Neuroscience, 2016, 9, 71.	1.4	24
99	Fragile X syndrome: A review of clinical management. Intractable and Rare Diseases Research, 2016, 5, 145-157.	0.3	70
100	Review of targeted treatments in fragile X syndrome. Intractable and Rare Diseases Research, 2016, 5, 158-167.	0.3	28
101	Alcohol use dependence in fragile X syndrome. Intractable and Rare Diseases Research, 2016, 5, 207-213.	0.3	8
102	Warburg effect linked to cognitiveâ€executive deficits in <i>FMR1</i> premutation. FASEB Journal, 2016, 30, 3334-3351.	0.2	33
103	Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial. Scientific Reports, 2016, 6, 21719.	1.6	26
104	Psychopathology Increases With Age in Fragile X Carrier Mothers. Biological Psychiatry, 2016, 79, 790-791.	0.7	0
105	Altered Bioenergetics in Primary Dermal Fibroblasts from Adult Carriers of the FMR1 Premutation Before the Onset of the Neurodegenerative Disease Fragile X-Associated Tremor/Ataxia Syndrome. Cerebellum, 2016, 15, 552-564.	1.4	41
106	Clinicians' experiences with the fragile X clinical and research consortium. American Journal of Medical Genetics, Part A, 2016, 170, 3138-3143.	0.7	6
107	Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 328-337.	1.2	15
108	Developmental profiles of infants with an FMR1 premutation. Journal of Neurodevelopmental Disorders, 2016, 8, 40.	1.5	21

#	Article	IF	Citations
109	Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1139-1147.	1.1	21
110	Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the <i>FMR1</i> premutation. Biochemical Journal, 2016, 473, 3871-3888.	1.7	38
111	Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome. Science Signaling, 2016, 9, ra58.	1.6	49
112	A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2016, 37, 619-628.	0.6	65
113	Fragile X-associated tremor/ataxia syndrome — features, mechanisms and management. Nature Reviews Neurology, 2016, 12, 403-412.	4.9	221
114	Aging in Fragile X Premutation Carriers. Cerebellum, 2016, 15, 587-594.	1.4	14
115	Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers. Cerebellum, 2016, 15, 578-586.	1.4	35
116	Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning. Clinical Neuropsychologist, 2016, 30, 944-959.	1.5	14
117	Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Science Translational Medicine, 2016, 8, 321ra5.	5.8	210
118	Phenobarbital use and neurological problems in FMR1 premutation carriers. NeuroToxicology, 2016, 53, 141-147.	1.4	20
119	Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism. Psychopharmacology, 2016, 233, 309-323.	1.5	43
120	Treatment and Management of FXTAS. , 2016, , 181-197.		4
121	Robust Machine Learning-Based Correction on Automatic Segmentation of the Cerebellum and Brainstem. PLoS ONE, 2016, 11, e0156123.	1.1	18
122	Clinical and Molecular Assessment in a Female with Fragile X Syndrome and Tuberous Sclerosis. Journal of Genetic Disorders & Genetic Reports, 2016, 5, .	0.1	1
123	Detection of skewed X-chromosome inactivation in Fragile X syndrome and X chromosome aneuploidy using quantitative melt analysis. Expert Reviews in Molecular Medicine, 2015, 17, e13.	1.6	12
124	A feasibility trial of Cogmed working memory training in fragile X syndrome. Journal of Pediatric Genetics, 2015, 03, 147-156.	0.3	13
125	Psychosis and catatonia in fragile X: Case report and literature review. Intractable and Rare Diseases Research, 2015, 4, 139-146.	0.3	12
126	Methadone use in a male with the <i>FMRI</i> premutation and FXTAS. American Journal of Medical Genetics, Part A, 2015, 167, 1354-1359.	0.7	24

#	Article	IF	CITATIONS
127	Axonal neuropathy in female carriers of the fragile X premutation with fragile x–associated tremor ataxia syndrome. Muscle and Nerve, 2015, 52, 234-239.	1.0	5
128	High functioning male with fragile X syndrome and fragile Xâ€essociated tremor/ataxia syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 2154-2161.	0.7	28
129	Identification of a male with fragile X syndrome through newborn screening. Intractable and Rare Diseases Research, 2015, 4, 198-202.	0.3	3
130	Fragile X–Associated Tremor/Ataxia Syndrome in a Man in His 30s. JAMA Neurology, 2015, 72, 1070.	4.5	26
131	Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome. Brain Research, 2015, 1598, 88-96.	1.1	41
132	Use of Emotional Cues for Lexical Learning: A Comparison of Autism Spectrum Disorder and Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2015, 45, 1042-1061.	1.7	10
133	Fragile X–associated tremor/ataxia syndrome. Annals of the New York Academy of Sciences, 2015, 1338, 58-70.	1.8	139
134	Effect of Speaker Gaze on Word Learning in Fragile X Syndrome: A Comparison With Nonsyndromic Autism Spectrum Disorder. Journal of Speech, Language, and Hearing Research, 2015, 58, 383-395.	0.7	9
135	Maternal Consequences of the Detection of Fragile X Carriers in Newborn Screening. Pediatrics, 2015, 136, e433-e440.	1.0	14
136	Treatment of the psychiatric problems associated with fragile X syndrome. Current Opinion in Psychiatry, 2015, 28, 107-112.	3.1	40
137	Symptoms of Autism in Males with Fragile X Syndrome: A Comparison to Nonsyndromic ASD Using Current ADI-R Scores. Journal of Autism and Developmental Disorders, 2015, 45, 1925-1937.	1.7	74
138	Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder. Current Pharmaceutical Design, 2015, 21, 4972-4979.	0.9	20
139	Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. Intractable and Rare Diseases Research, 2015, 4, 123-130.	0.3	39
140	Translational research guided by animal studies in Fragile X Disorders. Intractable and Rare Diseases Research, 2014, 3, 100-100.	0.3	0
141	Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable and Rare Diseases Research, 2014, 3, 110-117.	0.3	25
142	Immune Dysregulation as a Cause of Autoinflammation in Fragile X Premutation Carriers: Link between FMRI CGG Repeat Number and Decreased Cytokine Responses. PLoS ONE, 2014, 9, e94475.	1.1	26
143	Modulation of the GABAergic pathway for the treatment of fragile X syndrome. Neuropsychiatric Disease and Treatment, 2014, 10, 1769.	1.0	62
144	Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases. Intractable and Rare Diseases Research, 2014, 3, 162-165.	0.3	34

#	Article	IF	CITATIONS
145	Participation of underrepresented minority children in clinical trials for Fragile X syndrome and other neurodevelopmental disorders. Intractable and Rare Diseases Research, 2014, 3, 147-152.	0.3	5
146	Clinical and molecular implications of mosaicism in FMR1 full mutations. Frontiers in Genetics, 2014, 5, 318.	1.1	86
147	Towards an understanding of neuropsychiatric manifestations in fragile X premutation carriers. Future Neurology, 2014, 9, 227-239.	0.9	29
148	Fatigue and body mass index in the Fragile X premutation carrier. Fatigue: Biomedicine, Health and Behavior, 2014, 2, 64-72.	1.2	6
149	Fragile X spectrum disorders. Intractable and Rare Diseases Research, 2014, 3, 134-146.	0.3	150
150	Fragile X Premutation. Journal of Neurodevelopmental Disorders, 2014, 6, 22.	1.5	20
151	Genomic studies in fragile X premutation carriers. Journal of Neurodevelopmental Disorders, 2014, 6, 27.	1.5	24
152	Psychiatric symptoms in boys with fragile X syndrome: A comparison with nonsyndromic autism spectrum disorder. Research in Developmental Disabilities, 2014, 35, 1072-1086.	1.2	65
153	Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): Revisited. Parkinsonism and Related Disorders, 2014, 20, 456-459.	1.1	42
154	CGG allele size somatic mosaicism and methylation in <i>FMR1</i> premutation alleles. Journal of Medical Genetics, 2014, 51, 309-318.	1.5	76
155	The challenges of clinical trials in fragile X syndrome. Psychopharmacology, 2014, 231, 1237-1250.	1.5	98
156	Early Detection of Fragile X Syndrome: Applications of a Novel Approach for Improved Quantitative Methylation Analysis in Venous Blood and Newborn Blood Spots. Clinical Chemistry, 2014, 60, 963-973.	1.5	43
157	Memantine Effects on Verbal Memory in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): a Double-Blind Brain Potential Study. Neuropsychopharmacology, 2014, 39, 2760-2768.	2.8	36
158	The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery. Stem Cells Translational Medicine, 2014, 3, 1275-1286.	1.6	24
159	Effects of labeling and pointing on object gaze in boys with fragile X syndrome: An eye-tracking study. Research in Developmental Disabilities, 2014, 35, 2658-2672.	1.2	11
160	Associated features in females with an FMR1 premutation. Journal of Neurodevelopmental Disorders, 2014, 6, 30.	1.5	116
161	Emerging topics in FXTAS. Journal of Neurodevelopmental Disorders, 2014, 6, 31.	1.5	76
162	Emotion Potentiated Startle in Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2014, 44, 2536-2546.	1.7	7

#	Article	IF	CITATIONS
163	ERP abnormalities elicited by word repetition in fragile X-associated tremor/ataxia syndrome (FXTAS) and amnestic MCI. Neuropsychologia, 2014, 63, 34-42.	0.7	21
164	Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome. Neurobiology of Aging, 2014, 35, 1189-1197.	1.5	31
165	Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disorders & Therapy, 2014, 03, .	0.1	40
166	The Fragile X Mouse is Cured, Now for the Patients. Human Mutation, 2014, 35, v-v.	1.1	0
167	Memantine for Fragile X–Associated Tremor/Ataxia Syndrome. Journal of Clinical Psychiatry, 2014, 75, 264-271.	1.1	44
168	Translating Molecular Advances in Fragile X Syndrome Into Therapy. Journal of Clinical Psychiatry, 2014, 75, e294-e307.	1.1	46
169	Fragile X syndrome. Colombia Medica, 2014, 45, 190-8.	0.7	48
170	Fragile X–Associated Tremor/Ataxia Syndrome. JAMA Neurology, 2013, 70, 1022.	4.5	64
171	High MMPâ€9 activity levels in fragile X syndrome are lowered by minocycline. American Journal of Medical Genetics, Part A, 2013, 161, 1897-1903.	0.7	140
172	Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurology, The, 2013, 12, 786-798.	4.9	288
173	Intranuclear inclusions in a fragile X mosaic male. Translational Neurodegeneration, 2013, 2, 10.	3.6	37
174	A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Movement Disorders, 2013, 28, 1278-1284.	2.2	31
175	Phenotypes of hypofrontality in older female fragile x premutation carriers. Annals of Neurology, 2013, 74, n/a-n/a.	2.8	25
176	Electrocortical changes associated with minocycline treatment in fragile X syndrome. Journal of Psychopharmacology, 2013, 27, 956-963.	2.0	92
177	Epilepsy drives autism in neurodevelopmental disorders. Developmental Medicine and Child Neurology, 2013, 55, 101-102.	1.1	13
178	Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles. NeuroImage, 2013, 65, 288-298.	2.1	31
179	A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2013, 34, 147-155.	0.6	212
180	Neural Substrates of Executive Dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): a Brain Potential Study. Cerebral Cortex, 2013, 23, 2657-2666.	1.6	28

#	Article	IF	CITATIONS
181	Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Current Psychiatry Reviews, 2013, 9, 65-71.	0.9	21
182	Fragile X Syndrome: Psychiatric Manifestations, Assessment and Emerging Therapies. Current Psychiatry Reviews, 2013, 9, 53-58.	0.9	16
183	Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews, 2013, 9, 59-64.	0.9	18
184	Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews, 2013, 9, 59-64.	0.9	8
185	Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Human Molecular Genetics, 2012, 21, 2923-2935.	1.4	92
186	Age-Dependent Structural Connectivity Effects in Fragile X Premutation. Archives of Neurology, 2012, 69, 482-9.	4.9	51
187	Sertraline May Improve Language Developmental Trajectory in Young Children with Fragile X Syndrome: A Retrospective Chart Review. Autism Research & Treatment, 2012, 2012, 1-8.	0.1	37
188	Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome. Case Reports in Genetics, 2012, 2012, 1-4.	0.1	39
189	Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial. Science Translational Medicine, 2012, 4, 152ra127.	5.8	289
190	AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genetics in Medicine, 2012, 14, 729-736.	1.1	152
191	Immuneâ€mediated disorders among women carriers of fragile X premutation alleles. American Journal of Medical Genetics, Part A, 2012, 158A, 2473-2481.	0.7	86
192	FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Medicine, 2012, 4, 100.	3.6	258
193	Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. Journal of Clinical Investigation, 2012, 122, 4314-4322.	3.9	269
194	Fragile X Syndrome and Targeted Treatment Trials. Results and Problems in Cell Differentiation, 2012, 54, 297-335.	0.2	91
195	Signaling defects in iPSC-derived fragile X premutation neurons. Human Molecular Genetics, 2012, 21, 3795-3805.	1.4	129
196	Hypertension in <i>FMR1</i> premutation males with and without fragile Xâ€essociated tremor/ataxia syndrome (FXTAS). American Journal of Medical Genetics, Part A, 2012, 158A, 1304-1309.	0.7	41
197	Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Human Genetics, 2012, 131, 581-589.	1.8	108
198	Epigenetic Modification of the <i>FMR1</i> Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056. Science Translational Medicine, 2011, 3, 64ra1.	5.8	344

#	Article	IF	CITATIONS
199	Rare Intranuclear Inclusions in the Brains of 3 Older Adult Males With Fragile X Syndrome: Implications for the Spectrum of Fragile X-Associated Disorders. Journal of Neuropathology and Experimental Neurology, 2011, 70, 462-469.	0.9	33
200	Fragile X Syndrome. Current Genomics, 2011, 12, 216-224.	0.7	136
201	An fMRI study of the prefrontal activity during the performance of a working memory task in premutation carriers of the fragile X mental retardation 1 gene with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Journal of Psychiatric Research, 2011, 45, 36-43.	1.5	80
202	Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathologica, 2011, 122, 467-479.	3.9	102
203	Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. Journal of Neurodevelopmental Disorders, 2011, 3, 57-67.	1.5	269
204	FMR1 premutation and full mutation molecular mechanisms related to autism. Journal of Neurodevelopmental Disorders, 2011, 3, 211-224.	1.5	74
205	Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Molecular Autism, $2011, 2, 2$ .	2.6	68
206	Diffusion tensor imaging in male premutation carriers of the fragile X mental retardation gene. Movement Disorders, 2011, 26, 1329-1336.	2.2	72
207	Sleep apnea in fragile X premutation carriers with and without FXTAS. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 923-928.	1.1	51
208	Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. Rheumatology, 2011, 50, 2233-2236.	0.9	51
209	A voxel-based morphometry study of grey matter loss in fragile X-associated tremor/ataxia syndrome. Brain, 2011, 134, 863-878.	3.7	87
210	Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Human Molecular Genetics, 2011, 20, 3079-3092.	1.4	98
211	Lifetime Prevalence of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Journal of Clinical Psychiatry, 2011, 72, 175-182.	1.1	162
212	Improving Fragile X-Associated Tremor/Ataxia Syndrome Symptoms With Memantine and Venlafaxine. Journal of Clinical Psychopharmacology, 2010, 30, 642-644.	0.7	26
213	Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochemical Journal, 2010, 429, 545-552.	1.7	162
214	Aging in fragile X syndrome. Journal of Neurodevelopmental Disorders, 2010, 2, 70-76.	1.5	59
215	Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Molecular Autism, 2010, 1, 12.	2.6	204
216	Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Human Molecular Genetics, 2010, 19, 196-208.	1.4	143

#	Article	IF	CITATIONS
217	Abnormal N400 word repetition effects in fragile X-associated tremor/ataxia syndrome. Brain, 2010, 133, 1438-1450.	3.7	24
218	Side Effects of Minocycline Treatment in Patients With Fragile X Syndrome and Exploration of Outcome Measures. American Journal on Intellectual and Developmental Disabilities, 2010, 115, 433-443.	0.8	90
219	Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. NeuroToxicology, 2010, 31, 399-402.	1.4	40
220	The Efficacy of Melatonin for Sleep Problems in Children with Autism, Fragile X Syndrome, or Autism and Fragile X Syndrome. Journal of Clinical Sleep Medicine, 2009, 05, 145-150.	1.4	149
221	Advances in the Treatment of Fragile X Syndrome. Pediatrics, 2009, 123, 378-390.	1.0	513
222	A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. Journal of Neurodevelopmental Disorders, 2009, 1, 33-45.	1.5	156
223	A Quantitative ELISA Assay for the Fragile X Mental Retardation 1 Protein. Journal of Molecular Diagnostics, 2009, 11, 281-289.	1.2	52
224	The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. Journal of Clinical Sleep Medicine, 2009, 5, 145-50.	1.4	82
225	Expanded clinical phenotype of women with the <i>FMR1</i> premutation. American Journal of Medical Genetics, Part A, 2008, 146A, 1009-1016.	0.7	290
226	Impact of the Fragile X mental retardation 1 ( <i>FMR1</i> ) gene premutation on neuropsychiatric functioning in adult males without fragile Xâ€associated Tremor/Ataxia syndrome: A controlled study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 859-872.	1.1	64
227	Dementia in fragile Xâ€associated tremor/ataxia syndrome (FXTAS): Comparison with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1138-1144.	1.1	92
228	The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 853-869.	0.8	83
229	Testing for Fragile X Gene Mutations Throughout the Life Span. JAMA - Journal of the American Medical Association, 2008, 300, 2419.	3.8	33
230	Abnormal Nerve Conduction Features in Fragile X Premutation Carriers. Archives of Neurology, 2008, 65, 495.	4.9	75
231	Autism Profiles of Males With Fragile X Syndrome. American Journal on Intellectual and Developmental Disabilites, 2008, 113, 427-438.	2.7	357
232	Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome Neuropsychology, 2008, 22, 48-60.	1.0	167
233	Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clinical Interventions in Aging, 2008, Volume 3, 251-262.	1.3	122
234	The Prader-Willi Phenotype of Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2007, 28, 133-138.	0.6	139

#	Article	IF	CITATIONS
235	Testicular and Pituitary Inclusion Formation in Fragile X Associated Tremor/Ataxia Syndrome. Journal of Urology, 2007, 177, 1434-1437.	0.2	94
236	Neuropathic features in fragile X premutation carriers. American Journal of Medical Genetics, Part A, 2007, 143A, 19-26.	0.7	89
237	Neuropathy as a presenting feature in fragile Xâ€associated tremor/ataxia syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 2256-2260.	0.7	59
238	CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 566-569.	1.1	138
239	Progression of tremor and ataxia in male carriers of the FMR1 premutation. Movement Disorders, 2007, 22, 203-206.	2.2	134
240	Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Movement Disorders, 2007, 22, 645-650.	2.2	84
241	Fragile Xâ€associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Movement Disorders, 2007, 22, 2018-2030.	2.2	306
242	Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. General Hospital Psychiatry, 2007, 29, 349-356.	1.2	83
243	Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurology, The, 2007, 6, 45-55.	4.9	212
244	Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). Journal of the Neurological Sciences, 2006, 248, 227-233.	0.3	126
245	Lessons from Fragile X Regarding Neurobiology, Autism, and Neurodegeneration. Journal of Developmental and Behavioral Pediatrics, 2006, 27, 63-74.	0.6	181
246	Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder in Boys with the Fragile X Premutation. Journal of Developmental and Behavioral Pediatrics, 2006, 27, S137-S144.	0.6	292
247	Effect of CX516, an AMPA-Modulating Compound, on Cognition and Behavior in Fragile X Syndrome: AControlled Trial. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 525-540.	0.7	136
248	Psychiatric Phenotype of the Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) in Males. Journal of Clinical Psychiatry, 2006, 67, 87-94.	1.1	158
249	Recent advances in fragile X: a model for autism and neurodegeneration. Current Opinion in Psychiatry, 2005, 18, 490-496.	3.1	103
250	Response to letter: "No evidence of paternal transmission of fragile X syndrome―by Doris and Peter Steinbach. American Journal of Medical Genetics, Part A, 2005, 136A, 109-110.	0.7	0
251	Penetrance of the Fragile X–Associated Tremor/Ataxia Syndrome in a Premutation Carrier Population. JAMA - Journal of the American Medical Association, 2004, 291, 460.	3.8	571
252	The Fragile-X Premutation: A Maturing Perspective. American Journal of Human Genetics, 2004, 74, 805-816.	2.6	485

#	Article	IF	Citations
253	Tremor and ataxia in fragile X premutation carriers: Blinded videotape study. Annals of Neurology, 2003, 53, 616-623.	2.8	104
254	Fragile X Premutation Tremor/Ataxia Syndrome: Molecular, Clinical, and Neuroimaging Correlates. American Journal of Human Genetics, 2003, 72, 869-878.	2.6	720
255	Effect of the Fragile X Status Categories and the Fragile X Mental Retardation Protein Levels on Executive Functioning in Males and Females With Fragile X Neuropsychology, 2003, 17, 646-657.	1.0	113
256	The fragile X premutation: into the phenotypic fold. Current Opinion in Genetics and Development, 2002, 12, 278-283.	1.5	228
257	Tremor/Ataxia syndrome in fragile X carrier males. Movement Disorders, 2002, 17, 744-745.	2.2	30
258	Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. Rna, 2002, 8, 1482-8.	1.6	143
259	Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. American Journal of Neuroradiology, 2002, 23, 1757-66.	1.2	272
260	Discourse Processing in Women with Fragile X Syndrome: Evidence for a Deficit Establishing Coherence. Cognitive Neuropsychology, 2001, 18, 1-18.	0.4	39
261	Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. American Journal of Medical Genetics Part A, 2000, 94, 232-236.	2.4	154
262	Transcription of the FMR1 gene in individuals with fragile X syndrome. American Journal of Medical Genetics Part A, 2000, 97, 195-203.	2.4	192
263	Elevated Levels of FMR1 mRNA in Carrier Males: A New Mechanism of Involvement in the Fragile-X Syndrome. American Journal of Human Genetics, 2000, 66, 6-15.	2.6	756
264	Compound heterozygous female with fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 83, 318-321.	2.4	10
265	Tissue heterogeneity of theFMR1 mutation in a high-functioning male with fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 84, 233-239.	2.4	79
266	Strong similarities of the FMR1 mutation in multiple tissues: Postmortem studies of a male with a full mutation and a male carrier of a premutation. American Journal of Medical Genetics Part A, 1999, 84, 240-244.	2.4	51
267	FMRP expression as a potential prognostic indicator in fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 84, 250-261.	2.4	318
268	Fragile X syndrome and an isodicentric X chromosome in a woman with multiple anomalies, developmental delay, and normal pubertal development., 1999, 85, 197-201.		3
269	Psychopharmacological interventions in fragile X syndrome, fetal alcohol syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velocardiofacial syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 1999, 5, 305-313.	3.5	27
270	Sensoryâ€modulation disruption, electrodermal responses, and functional behaviors. Developmental Medicine and Child Neurology, 1999, 41, 608-615.	1.1	17

#	Article	IF	Citations
271	Tissue heterogeneity of the FMR1 mutation in a high-functioning male with fragile X syndrome., 1999, 84, 233.		5
272	FMRP expression as a potential prognostic indicator in fragile X syndrome., 1999, 84, 250.		9
273	Trajectories and profiles of adaptive behavior in males with fragile X syndrome: Multicenter studies. Journal of Autism and Developmental Disorders, 1996, 26, 287-301.	1.7	47
274	Molecular/clinical correlations in females with fragile X., 1996, 64, 340-345.		94
275	A controlled study of longitudinal IQ changes in females and males with fragile X syndrome. , 1996, 64, 350-355.		50
276	Experiences and attitudes concerning genetic testing and insurance in a Colorado population: A survey of families diagnosed with fragile X syndrome. , 1996, 64, 378-381.		28
277	Expanding the role of the genetic counselor. , 1996, 64, 382-387.		6
278	Molecular-clinical correlations in males with an expanded FMR1 mutation., 1996, 64, 388-394.		182
279	Molecular-clinical correlations in males with an expanded FMR1 mutation., 1996, 64, 388.		3
280	Adult fragile X syndrome: Neuropsychology, brain anatomy, and metabolism. American Journal of Medical Genetics Part A, 1995, 60, 480-493.	2.4	76
281	High functioning fragile X males: Demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. American Journal of Medical Genetics Part A, 1994, 51, 298-308.	2.4	213
282	Emotional and neurocognitive deficits in fragile X. American Journal of Medical Genetics Part A, 1994, 51, 378-385.	2.4	76
283	Behavioral and Psychiatric Disorders in Adult Male Carriers of Fragile X. Journal of the American Academy of Child and Adolescent Psychiatry, 1994, 33, 256-264.	0.3	89
284	Clinical conundrums in fragile X syndrome. Nature Genetics, 1992, 1, 157-158.	9.4	29
285	Heterozygous fragile X female: Historical, physical, cognitive, and cytogenetic features. American Journal of Medical Genetics Part A, 1991, 38, 269-274.	2.4	178
286	Fragile X checklist. American Journal of Medical Genetics Part A, 1991, 38, 283-287.	2.4	142
287	Mental impairment in cytogenetically positive fragile X females. American Journal of Medical Genetics Part A, 1991, 38, 503-504.	2.4	34
288	Cognitive profiles of the carrier fragile X woman. American Journal of Medical Genetics Part A, 1991, 38, 505-508.	2.4	35

#	Article	IF	CITATIONS
289	Neuropsychological dysfunction among affected heterozygous fragile X females. American Journal of Medical Genetics Part A, 1990, 35, 28-35.	2.4	60
290	Developmental Implications of Changing Trajectories of IQ in Males with Fragile X Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 1990, 29, 214-219.	0.3	75
291	Longitudinal IQ changes in fragile X males. American Journal of Medical Genetics Part A, 1989, 33, 513-518.	2.4	86
292	Aortic hypoplasia and cardiac valvular abnormalities in a boy with fragile X syndrome. American Journal of Medical Genetics Part A, 1988, 30, 83-98.	2.4	27
293	Cognitive profiles of boys with the fragile X syndrome. American Journal of Medical Genetics Part A, 1988, 30, 191-200.	2.4	121
294	A controlled trial of stimulant medication in children with the fragile X syndrome. American Journal of Medical Genetics Part A, 1988, 30, 377-392.	2.4	146
295	Invited editorial comment: Cognitive variability in the fragile X syndrome. American Journal of Medical Genetics Part A, 1987, 28, 13-15.	2.4	23
296	Cognitive profiles and the spectrum of clinical manifestations in heterozygous fra(X) females. American Journal of Medical Genetics Part A, 1986, 23, 139-156.	2.4	115
297	Oral findings in fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 179-187.	2.4	19
298	Aortic root dilatation and mitral valve prolapse in the fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 189-194.	2.4	60
299	Speech disturbances (cluttering) in mildly impaired males with the Martin-Bell/fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 195-206.	2.4	88
300	Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 241-262.	2.4	62
301	An analysis of autism in fifty males with the fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 359-374.	2.4	224
302	Autism in fragile X females. American Journal of Medical Genetics Part A, 1986, 23, 375-380.	2.4	55
303	Consideration of connective tissue dysfunction in the fragile X syndrome. American Journal of Medical Genetics Part A, 1984, 17, 111-121.	2.4	59
304	Autism spectrum disorder in the fragile X premutation state: possible mechanisms and implications. Journal of Neurology, 0, , .	1.8	7